CoChat

Molecular genetic testing of congenital adrenal hyperplasia due to 21-hydroxylase deficiency should include CAH-X chimeras

Open access
Lao, Qizong, Merke, Deborah P. · 2021 · European Journal of Human Genetics
Cited by 20

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

We read with great interest the European Molecular Genetics Quality Network practice guidelines for molecular genetic testing of congenital adrenal hyperplasia (CAH) due to CYP21A2 defects [ 1 ]. The authors address multiple important issues in the molecular genetic testing of CAH and provide valuable suggested standards based on extensive experience and practices from laboratories worldwide. While in general we agree with the workflow and methods described in the guidelines, we appeal to include evaluation for a contiguous gene deletion syndrome, termed CAH-X, within the scope of the testing. We believe this would be particularly beneficial for individuals carrying a CAH genotype of “30 kb deletion”. As illustrated in Fig. 2 of the article by Baumgartner-Parzer et al. [ 1 ], the terms “30 kb deletion” or “large gene conversion” refer to a CAH genotype of chimeric genes caused by unequal crossover during meiosis due to the structural complexity of the CYP21A2 locus. These deletions account for 20–30% of all CAH alleles and are categorized into two subtypes determined by the location of the junction sites: CAH and CAH-X chimeras [ 2 ]. CAH chimeras ( CYP21A1P/CYP21A2 ) are caused by recombination between CYP21A1P and CYP21A2 , and impair only CYP21A2 ; CAH-X chimeras ( CYP21A1P-TNXA/TNXB) are caused by recombination between TNXA and TNXB , null the entire CYP21A2 and replace the 3′ of neighboring TNXB with the pseudogene TNXA . This contiguous deletion is hence termed CAH-X, named for both CYP21A2 and TNXB defects. The latter is causative for hypermobility type Ehlers–Danlos syndrome (EDS) due to either deficiency or misfolding of its encoding tenascin-X, a crucial component of the extracellular matrix [ 3 , 4 , 5 ]. Unlike the well documented CAH chimeras, CAH-X chimeras have often been missed and are typically omitted from the scope of CAH testing, even though this contiguous gene deletion was first reported in 1997 [ 3 ]. As a result, CAH-X cases are reported as having a null CAH allele leading to lack of recognition and underestimation of CAH-X prevalence. In fact, the prevalence of CAH-X was recently estimated to be 15% in our large CAH cohort (278 subjects) in the U.S. followed at the National Institutes of Health Clinical Center (Bethesda, Maryland) and it was particularly prevalent (30%) in the “30 kb deletion” alleles [ 6 ]. Similarly, Gao et al. reported a 14% CAH-X prevalence in a large Chinese cohort (424 subjects) and a very high (59%) prevalence in CAH alleles previously reported as “deletion” or “null” [ 7 ]. These reports indicate the necessity of revisiting the prevalence of CAH-X chimeras and addressing potential clinical implications of the CAH-X syndrome, especially in subjects carrying an allele of “30 kb deletion” or “large gene conversion”. CAH-X syndrome is composed of two elements: CAH and hypermobility type EDS; the former is autosomal recessive but the latter appears to be autosomal dominant. If carrying a CAH-X allele, phenotypic EDS is expected regardless of the CAH status [ 2 ], although in general CAH patients have more severe EDS manifestations than their carrier counterparts [ 4 , 5 ]. The hypermobility EDS spectrum includes joint hypermobility, arthralgias, frequent joint dislocations, hernias and midline defects including cardiac structural abnormalities. Overall, about 25% of reported CAH-X patients have cardiac abnormalities including congenital heart defects such as structural valve abnormalities, left ventricular diverticulum, and patent foramen ovale [ 8 ]. To date, the clinical diagnosis of EDS in CAH-X mostly relies on evaluation of joint hypermobility and subluxations, which are often restricted by factors such as age and time of onset. Genetic testing for this germline condition in newborn screening is advantageous in terms of offering very early diagnosis to young children before hypermobility evaluation is applicable, and to enable early screening for cardiac defects. In older individuals undergoing CYP21A2 genotyping, identification of CAH-X would provide information regarding the cause of any ongoing connective tissue abnormalities and guidance regarding preventative measures. Treatment for hypermobility type EDS depends on the signs and symptoms present, and a screening echocardiogram should be considered. To date, most CAH genetic test platforms determine the status of “30 kb deletions”. Adding a CAH-X test selectively to “30 kb deletion” positives can be a pinpoint add-on. Sharing a ride with established DNA extraction and even PCR would optimize laboratory efficiency and cost-effectiveness. For instance, laboratories that use a classic CYP779f/tena32F primer pair for PCR can use the same PCR product to conduct Sanger sequencing tests of CAH variants, 30-kb deletions and CAH-X chimeras [ 9 , 10 ]. A high throughput CAH-X screening has been developed, which has shown excellent accuracy. It is amenable to either qPCR or digital PCR, thus it is fast and easy to

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41431-021-00870-5

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 20

Metadata

Authors
Lao, Q., & Merke, D. P.
Venue
European Journal of Human Genetics
Published
2021-04-07
Volume
29
Issue
7
Pages
1047-1048
ISSN
  • 1018-4813 (ISSN-L)
  • 1476-5438
OpenAlex
W3145243589
Cited by
20
References
9
FWCI
1.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular genetic testing of congenital adrenal hyperplasia due to 21-hydroxylase deficiency should include CAH-X chimeras. https://app.cochat.ai/papers/10.1038/s41431-021-00870-5
The paper
Lao, Q., & Merke, D. P. (2021). Molecular genetic testing of congenital adrenal hyperplasia due to 21-hydroxylase deficiency should include CAH-X chimeras. European Journal of Human Genetics. https://doi.org/10.1038/s41431-021-00870-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.